骨肉瘤患者应用大剂量甲氨蝶呤治疗的药动学研究

Pharmacokinetic research of large dose of methotrexate in osteosarcoma patient

目的:研究11例骨肉瘤患者应用大剂量甲氨蝶呤治疗的甲氨蝶呤(MTX)药动学过程,确定联合用药下MTX的药动学参数,为临床应用提供依据。方法:用荧光偏振免疫(FPIA)方法检测一定时间下的血清MTX浓度。结果:MTX半衰期(t1/2)、表观分布容积(Vd)、曲线下面积(AUC)、清除率(CL)、平均滞留时间(MRT)分别为8.38h、143.55L、1225.95mg.h.L-1、11.73mL.min-1、5.53h。结论:为大剂量MTX治疗骨肉瘤患者提供了客观有效的药动学数据,对临床应用大剂量MTX治疗骨肉瘤可靠性和安全性有重要的指导意义。

OBJECTIVE To observe the pharmacokinetics process of the large dose of methotrexate（MTX） in eleven patients of osteosarcoma, and determine the pharmacokinetic parameters in associated medication, for the purpose of providing the guide for clinical application. METHODS To detect the concentration of MTX in the serum of certain time-points with the method of FPIA. RESULTS The half life（t1/2 ）, Vd, AUC, CL and MRT of MTX were 8. 38 h, 143.55 L、1225.95 mg, h. L^-1 , 11. 73 mL·min^-1 ,5.53 h respectively. CONCLUSION The research offer the effective pharmacokinetics data for treat the osteosar coma with large dose MTX and can guide the reliability and safety of the MTX.